Minoxidil
This article was originally published in The Tan Sheet
Executive Summary
Foam delivery system for OTC hair loss treatment ingredient under development, Palo Alto, Calif.-based Connetics says in teleconference March 21. Firm may commercialize product itself or seek marketing partners; Rogaine marketer Pharmacia says it currently has no interest in alternative delivery forms. Connetics also developing foam delivery for ketoconazole 2% and plans to file an NDA during first half of 2002 upon completing clinical trial this year; the 2% dose (McNeil's Rx Nizoral) recently was associated with hair loss benefits, prompting McNeil to investigate a new indication (1"The Tan Sheet" March 12, p. 3). Connetics acquired Victoria, Australia-based Soltec Research for $16.9 mil. in cash March 20. Soltec developed a mousse delivery form for Bayer's Rid pediculicide approved March 2000
You may also be interested in...
Ketoconazole Positive Effects On Hair Loss Suggested By Study Data
Ketoconazole comparative studies with minoxidil 2% and zinc pyrithione 1% could be used to support a hair-loss treatment indication for McNeil Consumer Healthcare's Nizoral A-D anti-dandruff shampoo.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands